Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Enterprise Value (2016 - 2025)

Historic Enterprise Value for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to -$262.6 million.

  • Ani Pharmaceuticals' Enterprise Value fell 8111.39% to -$262.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$262.6 million, marking a year-over-year decrease of 8111.39%. This contributed to the annual value of -$144.9 million for FY2024, which is 3447.3% up from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Enterprise Value of -$262.6 million as of Q3 2025, which was down 8111.39% from -$217.8 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Enterprise Value ranged from a high of -$15.3 million in Q3 2021 and a low of -$262.6 million during Q3 2025
  • Over the past 5 years, Ani Pharmaceuticals' median Enterprise Value value was -$144.9 million (recorded in 2024), while the average stood at -$129.9 million.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Enterprise Value crashed by 71838.04% in 2021, and later skyrocketed by 4944.59% in 2022.
  • Over the past 5 years, Ani Pharmaceuticals' Enterprise Value (Quarter) stood at -$105.3 million in 2021, then surged by 49.45% to -$53.2 million in 2022, then crashed by 315.38% to -$221.1 million in 2023, then skyrocketed by 34.47% to -$144.9 million in 2024, then plummeted by 81.27% to -$262.6 million in 2025.
  • Its Enterprise Value was -$262.6 million in Q3 2025, compared to -$217.8 million in Q2 2025 and -$149.8 million in Q1 2025.